<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Moderate <z:hpo ids='HP_0001824'>weight loss</z:hpo> is recommended for overweight and <z:mp ids='MP_0001261'>obese</z:mp> patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and conjunctive use of <z:hpo ids='HP_0001824'>weight loss</z:hpo> medication has been advocated </plain></SENT>
<SENT sid="1" pm="."><plain>The current study examined <z:hpo ids='HP_0001824'>weight loss</z:hpo>-dependent and -independent effects of the intestinal lipase inhibitor orlistat at 6 months of treatment, using behavioral intervention (Int) combined with randomized, double-blinded, placebo (P)-controlled treatment with orlistat (O) </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: Metabolic control, insulin sensitivity (IS), regional fat distribution, and fat content in liver and muscle were measured in 39 volunteers with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in whom <z:hpo ids='HP_0000001'>all</z:hpo> <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> medication was withdrawn 1 month preceding randomization </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0001824'>Weight loss</z:hpo> was equivalent in the Int+O and Int+P groups, respectively (-10.3 +/- 1.3 vs. -8.9 +/- 1.1%), and there were identical decreases in visceral adipose tissue (VAT), fat mass (FM), thigh <z:e sem="disease" ids="C0028754" disease_type="Disease or Syndrome" abbrv="">adiposity</z:e>, and <z:hpo ids='HP_0001397'>hepatic steatosis</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:hpo ids='HP_0001824'>Weight loss</z:hpo> resulted in substantial improvement (P &lt; 0.001) in HbA(1c) (-1.6 +/- 0.3 vs. -1.0 +/- 0.4%; NS between groups) </plain></SENT>
<SENT sid="5" pm="."><plain>IS improved significantly more with orlistat (Delta2.2 +/- 0.4 vs. Delta1.2 +/- 0.4 mg </plain></SENT>
<SENT sid="6" pm="."><plain>min(-1) </plain></SENT>
<SENT sid="7" pm="."><plain>kg(-1) fat-free mass [FFM]; P &lt; 0.05), and plasma free fatty acid (FFA) levels were strongly correlated with IS (r = 0.56; P &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>Orlistat caused greater reductions in fasting plasma FFA (Delta-154 +/- 22 vs. Delta-51 +/- 33 micro mol/l; P &lt; 0.05), insulin-suppressed FFA (Delta-119 +/- 23 vs. Delta-87 +/- 34 micro mol/l; P &lt; 0.05), and fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (FPG; -62 +/- 9 vs. -32 +/- 8 mg/dl; P = 0.02) </plain></SENT>
<SENT sid="9" pm="."><plain>Changes in HbA(1c) were correlated with DeltaIS (r = -0.41; P &lt; 0.01) but not with <z:hpo ids='HP_0001824'>weight loss</z:hpo> per se </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: At equivalent <z:hpo ids='HP_0001824'>weight loss</z:hpo>, conjunctive use of orlistat resulted in greater improvement in FFA levels and IS </plain></SENT>
</text></document>